The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome
Meun, Cindy; Gunning, Marlise N.; Louwers, Yvonne, V; Peters, Henrike; Roos-Hesselink, Jolien; van Lennep, Jeanine Roeters; Rueda Ochoa, Oscar-Leonel; Appelman, Yolande; Lambalk, Nils; Boersma, Eric; Kavousi, Maryam; Fauser, Bart C. J. M.; Laven, Joop S. E.; Baart, Sara; Benschop, Laura; Brouwers, Laura; Budde, Ricardo; Cannegieter, Suzanne; Dam, Veerle; Eijkemans, Rene; Fauser, Bart C. J. M.; Ferrari, Michel; Franx, Arie; de Groot, Christianne; Gunning, Marlise N.; Hoek, Annemieke; Koffijberg, Erik; Koster, Wendy; Kruit, Mark; Lagerweij, Giske; Laven, Joop; Linstra, Katie; van der Lugt, Aad; Maas, Angela; van den Brink, Antoinette Maassen; Middeldorp, Saskia; Moons, Karel G. M.; van Rijn, Bas; Scheres, Luuk; van der Schouw, Yvonne T.; Steegers, Eric; Steegers, Regine; Terwindt, Gisela; Velthuis, Birgitta; Wermer, Marieke; Zick, Bart; Zoet, Gerbrand
(2020) Clinical Endocrinology, volume 92, issue 2, pp. 150 - 158
(Article)
Abstract
OBJECTIVES: Contradictory results have been reported regarding the association between polycystic ovary syndrome (PCOS) and cardiovascular disease (CVD). We assessed the cardiometabolic phenotype and prevalence of CVD in middle-aged women with PCOS, compared with age-matched controls from the general population, and estimated 10-year CVD risk and cardiovascular health score. DESIGN:
... read more
A cross-sectional study. PARTICIPANTS: 200 women aged >45 with PCOS, and 200 age-matched controls. MEASUREMENTS: Anthropometrics, insulin, lipid levels, prevalence of metabolic syndrome and type II diabetes. Ten-year Framingham risk score and the cardiovascular health score were calculated, and carotid intima-media thickness (cIMT) was measured. RESULTS: Mean age was 50.5 years (SD = 5.5) in women with PCOS and 51.0 years (SD = 5.2) in controls. Increased waist circumference, body mass index and hypertension were more often observed in women with PCOS (P < .001). In women with PCOS, the prevalence of type II diabetes and metabolic syndrome was not significantly increased and lipid levels were not different from controls. cIMT was lower in women with PCOS (P < .001). Calculated cardiovascular health and 10-year CVD risk were similar in women with PCOS and controls. CONCLUSIONS: Middle-aged women with PCOS exhibit only a moderately unfavourable cardiometabolic profile compared to age-matched controls, even though they present with an increased BMI and waist circumference. Furthermore, we found no evidence for increased (10-year) CVD risk or more severe atherosclerosis compared with controls from the general population. Long-term follow-up of women with PCOS is necessary to provide a definitive answer concerning long-term risk for CVD.
show less
Download/Full Text
Keywords: cardiovascular disease (7), polycystic ovary syndrome, Endocrinology, Endocrinology, Diabetes and Metabolism, Journal Article
ISSN: 0300-0664
Publisher: Wiley-Blackwell
Note: Funding Information: The current study was funded by the Dutch Heart Foundation, grant number?2013T083 (MNG., CM). BCJMF has received fees and grant support from the following organizations (in alphabetic order): Abbott, Controversies in Obstetrics & Gynecology (COGI), Dutch?Heart Foundation (Hartstichting), Dutch Medical Research Counsel (ZonMW), Ferring, London Womens Clinic (LWC), Menogenix, Myovant, OvaScience, Pantharei Bioscience, PregLem/Gedeon Richter,?Reproductive Biomedicine Online (RBMO), Teva/Theramex and World Health Organization (WHO). JSEL has received fees and grant support from the following organizations (in alphabetic order): Danone, Dutch Heart Foundation, Euroscreen, Ferring, Roche, Titus Healthcare and ZonMW. CBL has over the most recent 5?year period received fees and grant support from the following organizations (in?alphabetic order): Amsterdam UMC, Ferring, Merck and ZonMW. MK is supported by a VENI grant from the Netherlands Organization for Scientific Research (VENI 91616079). Funding Information: The current study was funded by the Dutch Heart Foundation, grant number 2013T083 (MNG., CM). BCJMF has received fees and grant support from the following organizations (in alphabetic order): Abbott, Controversies in Obstetrics & Gynecology (COGI), Dutch Heart Foundation (Hartstichting), Dutch Medical Research Counsel (ZonMW), Ferring, London Womens Clinic (LWC), Menogenix, Myovant, OvaScience, Pantharei Bioscience, PregLem/Gedeon Richter, Reproductive Biomedicine Online (RBMO), Teva/Theramex and World Health Organization (WHO). JSEL has received fees and grant support from the following organizations (in alphabetic order): Danone, Dutch Heart Foundation, Euroscreen, Ferring, Roche, Titus Healthcare and ZonMW. CBL has over the most recent 5 year period received fees and grant support from the following organizations (in alphabetic order): Amsterdam UMC, Ferring, Merck and ZonMW. MK is supported by a VENI grant from the Netherlands Organization for Scientific Research (VENI 91616079). Publisher Copyright: © 2019 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd
(Peer reviewed)